-
Mercati
-
Azioni
Sustainable finance2025 Euronext ESG Trends ReportLeggi tuttoA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indici
Access the white paperInvesting in the future of Europe with innovative indicesLeggi tuttoThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETF
The European market place for ETFsEuronext ETF EuropeLeggi tuttoInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Fondi
-
Obbligazioni
European Defence BondsGroupe BPCE lists the first bondLeggi tuttoFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Prodotti strutturati
-
Derivati
Where European Government Bonds Meet the FutureFixed Income derivativesLeggi tuttoTrade mini bond futures on main European government bonds
-
Commodities
- Panoramica
- Quotes snapshot
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Salmon derivatives
- Consegna e liquidazione
- Specifiche e disposizioni
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesLeggi tuttoEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Documenti e risorse
Designed to help students navigate the complexities of financial marketsEuronext Trading gameLeggi tuttoJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 27 Dec 2022 07:45 CET |
NANOBIOTIX | NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer | 20103010 Biotechnology | Corporate life |
| 27 Dec 2022 07:45 CET |
NANOBIOTIX | NANOBIOTIX annonce la randomisation du premier patient aux États-Unis dans l’essai pivot mondial de Phase 3 évaluant le radioenhancer NBTXR3 dans le cancer de la tête et du cou | 20103010 Biotechnology | Corporate life |
| 21 Dec 2022 22:15 CET |
NANOBIOTIX | NANOBIOTIX ANNONCE LA RÉSILIATION DE SON CONTRAT DE LIQUIDITÉ ET PRÉSENTE LE BILAN DE FIN DE CONTRAT | 20103010 Biotechnology | Legal |
| 08 Dec 2022 22:15 CET |
NANOBIOTIX | INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL | 20103010 Biotechnology | Corporate life |